For example, ITIL-306 is an autologous TIL therapy that combines T cell receptor-specific antigen recognition (against the HLA-A *02/MART-1 antigen) with the costimulatory signal of anti-FRα, designed to increase TIL activity in the presence of FRα-expressing tumor cells. This evidence concerns the gene FOLR1 and neoplasm.